The revenue spike is not sustainable as it stems from one-time transactions; traders should focus on enrollment progress in the AVIM and Virtue SAB pivotal trials as next key catalysts. Strong cash position reduces near-term dilution risk.
Price Chart
Executive Summary
Orchestra BioMed reported full-year 2025 financial results with revenue surging to $33.5 million (up 1,539% YoY) due to non-recurring items including termination of a Terumo agreement and a right-of-first-refusal deal, while net loss narrowed to $52.7 million. The company maintains a strong $106.5 million cash position and has $35 million in committed funding from Medtronic and Ligand, supporting pivotal trials for its AVIM and Virtue SAB programs.
Key Financial Metrics
Key Facts
- Revenue increased to $33.5 million in 2025 from $2.6 million in 2024, driven by $15.4 million in deferred revenue recognition, $10.0 million ROFR fee, and $7.4 million preferred stock premium from Terumo.
- Net loss attributable to common stockholders decreased to $52.7 million ($1.11/share) from $61.0 million ($1.66/share) in 2024.
- Cash and marketable securities totaled $106.5 million as of December 31, 2025, with $35 million expected from Medtronic and Ligand by May 1, 2026.
- BACKBEAT global pivotal trial for AVIM Therapy showed accelerated enrollment; Virtue SAB U.S. pivotal trial initiated in Q4 2025.
- Haemonetics acquired Vivasure Medical, with Orchestra expecting up to $10.7 million in 2026 proceeds.
Financial Impact
Revenue increased by $30.9 million year-over-year, but primarily due to non-recurring items; operating cash burn increased to $66.9 million in 2025 from $50.8 million in 2024.
Risk Factors
- Revenue growth is largely non-recurring and not indicative of ongoing commercial performance.
- Pivotal trials may face delays or negative outcomes, impacting valuation given the company's reliance on these programs.
- Future equity issuance possible if additional capital is needed beyond current commitments.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3254603 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 1, 2026 26d ago | 144 | $6.35 $5.73 | ▼ −9.76% | ▼ −11.06% | $5.59 (−11.97%) |
Oct 1, 2026 26d ago | 8-K | $6.35 $5.73 | ▼ −9.76% | ▼ −11.06% | $5.59 (−11.97%) |
Sep 22, 2026 4w ago | Institutional Cluster | $6.22 $6.08 | ▼ −2.25% | ▼ −1.06% | $5.59 (−10.13%) |
Sep 8, 2026 7w ago | Insider Cluster | $5.43 $6.04 | ▲ +11.23% | ▲ +12.35% | $5.59 (+2.95%) |
Sep 1, 2026 8w ago | 144 | $4.90 $5.45 | ▼ −11.22% | ▼ −11.14% | $5.59 (−14.08%) |
Jul 1, 2026 16w ago | 144 | $4.30 $3.96 | ▼ −7.91% | ▼ −8.17% | $5.59 (+30.00%) |
Jun 2, 2026 20w ago | Insider Cluster | $3.86 $4.02 | ▲ +4.15% | ▲ +7.96% | $5.59 (+44.82%) |
May 19, 2026 23w ago | Insider Cluster | $4.00 $4.06 | ▲ +1.50% | ▼ −0.75% | $5.59 (+39.75%) |
Apr 29, 2026 25w ago | DEFA14A | $3.99 $3.93 | ▼ −1.50% | ▼ −3.23% | $5.59 (+40.10%) |
Apr 23, 2026 26w ago | Press Release | $4.15 $3.80 | ▼ −8.43% | ▼ −9.91% | $5.59 (+34.70%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers